The United States Food and Drug Administration (FDA) granted accelerated approval for a new medication to treat Duchenne muscular dystrophy (DMD). The drug, Eteplirsen, was developed by a UK consortium led by Novel Therapies Theme lead, Professor Francesc
BRC-supported Dr Philippa Mills, Professor Peter Clayton and Professor Paul Gissen have led an investigation into the effectiveness of a gene panel, targeting 614 genes, in establishing a diagnosis for patients presenting with a wide array of neurometabol
The North Thames Genomic Medicine Centre’s (GMC) has recruited 5,200 genomes to the 100,000 Genomes project for rare diseases, making up around 28% of those recruited nationally.
In a new editorial published in Human Gene Therapy, leading researchers call for urgent action to ensure continued access to critical funding and ongoing collaborative opportunities with the broader scientific community in the European Union.
Research led by BRC-funded Professor Lucy Wedderburn has shown that muscle pathology and myositis-specific antibodies (MSA) predict the risk of remaining on treatment in Juvenile Dermatomyositis (JDM). These findings could aid risk stratification.